Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Research analysts at assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZSGet Free Report) (TSE:AEZ) in a report released on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their target price on Aeterna Zentaris from $28.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, November 13th.

Check Out Our Latest Stock Analysis on AEZS

Aeterna Zentaris Price Performance

Shares of Aeterna Zentaris stock opened at $1.79 on Friday. The business’s 50 day simple moving average is $2.01 and its two-hundred day simple moving average is $2.21. The stock has a market capitalization of $8.70 million, a P/E ratio of -0.37 and a beta of 1.66. Aeterna Zentaris has a one year low of $1.36 and a one year high of $3.90.

Aeterna Zentaris (NASDAQ:AEZSGet Free Report) (TSE:AEZ) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.24). Aeterna Zentaris had a negative return on equity of 49.10% and a negative net margin of 340.56%. Sell-side analysts expect that Aeterna Zentaris will post -3.22 earnings per share for the current fiscal year.

About Aeterna Zentaris

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Articles

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.